The effect of a newly developed patch treatment for disc hernia

ISRCTN ISRCTN06273186
DOI https://doi.org/10.1186/ISRCTN06273186
Secondary identifying numbers ARTC0001CL
Submission date
12/12/2013
Registration date
09/01/2014
Last edited
09/01/2014
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Treatment of low back pain and neck pain in cases of disc hernia involves drugs, physical
therapy and surgery in severe cases. This new drug is a patch that is easy to apply by sticking onto the skin. The aim of this study is to find out if this patch treatment is effective in reducing low back pain or neck pain due to disc hernia.

Who can participate?
Any patient suffering from back and neck pain aged between 20 to 60 years can take part in the study. Healthy volunteers of the same age range can also take part in the study.

What does the study involve?
Patients will be given the patch treatment if the pain is not resolved by drugs or physical therapy. We will also give the patch to healthy participants for comparison. Participants will have to rest completely during treatment. Pain before and after the treatment will be measured. Patients will also undergo a magnetic resonance examination before and after the treatment.

What are the possible benefits and risks of participating?
The most important side effect of the treatment is local rash in the skin where the patch is attached. There are no other side effects expected from the patch.

Where is the study run from?
Neurosurgery Department of Yildirim Beyazit Education and Research Hospital, Turkey.

When is study starting and how long is it expected to run for?
The study will run between January 2014 and February 2014.

Who is funding the study?
Metuas Medical Company, Turkey.

Who is the main contact?
Dr Mehmet Sorar
msorar@gmail.com

Contact information

Dr Gulsah Bayram Kabacam
Scientific

Bagcilar Mah. Acin Cad. 281. Sok 3/10 GOP
Ankara
06670
Türkiye

Study information

Study designSingle-center controlled trial
Primary study designInterventional
Secondary study designNon randomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleA pilot controlled study on the efficacy of a diffusional patch (ArtCure®) for the treatment of disc hernia
Study objectivesArtcure diffusional patch is safe and effective for the treatment of disc hernia.
Ethics approval(s)Kecioren Education and Research Hospital board of ethics, 15/03/2012, ref: 15.03.2012/B.10.4.İSM.4.06/68/49
Health condition(s) or problem(s) studiedDisc hernia/low back pain/neck pain
InterventionArtcure patch treatment with complete bed rest in disc hernia and healthy control cases.

All of the cases admitted to the hospital with cervical or lumbar disc herniation that is resistant to medical and physical therapy will be taken into the study if they fill in the informed consent form. Pre-treatment neurological examination and semi-quantitative, subjective pain assessment using the Visual Analog Scale (VAS) scoring from 0 (no pain) to 10 (most severe pain) will be carried out. Diagnosis and extent of the hernia will be confirmed by MRI examination. The Artcure® diffusional patch will be attached to the level of herniation, taking care that the central part of the patch is at the same level as the hernia. Patients then have 24 hours of absolute bed rest. At the end of this period the patch will be removed. Post-treatment assessment will be comprised of a second neurological examination. VAS scores for pain assessment will be determined 24 and 48 hours after the treatment. Control MRI examinations with the same sequences will be done in 6-8 weeks post-treatment.
Intervention typeOther
Primary outcome measure1. Complete resolution of the pain [48 hours post-treatment visual analogue scale (VAS) score = 0]
2. More than 5 points decrease in the VAS score in the 48 hours post-treatment
3. Complete resolution of the neurologic deficit in 48 hours
Secondary outcome measures1. VAS and neurological examinations will be performed at the baseline, 24 and 48 hours after the treatment
2. Pre- and post-treatment MRIs will be taken before the treatment and 6-8 weeks after the treatment
Overall study start date01/01/2014
Completion date01/02/2014

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants40 patients and 40 control cases
Key inclusion criteria1. Patients with severe low back or neck pain due to disc hernia between the ages of 20 and 60 who are willing to take part
2. Age-matched healthy control cases without low back pain and disc hernia
Key exclusion criteria1. Severe para-vertebral muscle spasm
2. Lumbar spinal stenosis
3. Foraminal stenosis
4. Calcified lumbar or cervical hernia
5. Loss of cervical or lumbar lordosis accompanying disc hernia
6. Loss of strength in any muscle group more than 2/5
7. Known dermal atophy
8. Accompanying asthma
Date of first enrolment01/01/2014
Date of final enrolment01/02/2014

Locations

Countries of recruitment

  • Türkiye

Study participating centre

Bagcilar Mah. Acin Cad. 281. Sok 3/10 GOP
Ankara
06670
Türkiye

Sponsor information

Metuas Medical Company (Turkey)
Industry

Turan Gunes Bulvari 75/7 Cankaya
Ankara
06550
Türkiye

Email msorar@gmail.com

Funders

Funder type

Industry

Metuas Medical Company (Turkey)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan